Checkpoint Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Checkpoint Therapeutics

13/05/2022 21:13

* Checkpoint Therapeutics Inc  CKPT.OQ  reported a quarterly
adjusted loss of 20 cents​​ per share for the quarter ended in
March. The mean expectation of five analysts for the quarter was
for a loss of 14 cents per share.
    * Revenue fell 23.5% to $52.00 thousand from a year ago; 
analysts
expected $17.50 thousand. 
    * Checkpoint Therapeutics Inc's reported EPS for the quarter
was a
loss of 20 cents​.
    * The mean earnings estimate of analysts had risen by
about 16.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Checkpoint Therapeutics Inc shares had fallen by 38.4%
this
quarter and lost 65.0% so far this year.
    * The company reported a quarterly loss of $16.85 million.
    * Wall Street's median 12-month price target for Checkpoint
Therapeutics Inc is $20.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 13 at 08:12 p.m.  ​All
figures in US dollars unless otherwise stated